Table 1

Baseline characteristics of the intention-to-treat population

Beclomethasone arm (N=193)Placebo arm (N=192)
Mean age, SD (years)51.8 (17.3)51.1 (18.6)
Sex, female, n (%)99 (51.3%)99 (51.9%)
Body mass index, mean (SD) kg/m224.8 (5.2)24.1 (5.4)
Medical history, n (%)
 Cardiovascular diseases4 (2.1%)1 (0.5%)
 Diabetes mellitus65 (33.7%)66 (34.4%)
 Hypertension62 (32.1%)62 (32.3%)
 Past or current history of asthma9 (4.7%)7 (3.6%)
 Other chronic respiratory conditions0 (0.0%)0 (0.0%)
 Treatment with ACEI, n (%)23 (11.9%)26 (13.5%)
 Vaccinated with one dose against COVID-19, n (%)124 (64.2%)113 (58.9%)
 Vaccinated with two doses against COVID-19, n (%)74 (38.8%)70 (36.5%)
Duration of symptoms before admission
Mean, (SD) days3.7 (1.9)3.9 (1.9)
COVID-19 severity on admission, n (%)
 Asymptomatic disease13 (6.7%)12 (6.3%)
 Mild disease122 (63.2%)123 (64.1%)
 Moderate disease58 (30.1%)57 (29.7%)
Prevalence of different symptoms on admission, n (%)
Cough115 (59.6%)123 (64.1%)
Fever109 (56.5%)112 (58.3%)
Sore throat67 (34.7%)71 (37.0%)
Fatigue60 (31.1%)75 (39.1%)
Loss of sense of smell or taste60 (31.1%)89 (46.4%)
Breathlessness59 (30.6%)58 (30.2%)
Myalgia58 (30.1%)66 (34.4%)
Gastrointestinal symptoms36 (18.7%)37 (19.3%)
Loss of appetite34 (17.6%)29 (15.1%)
Chest pain or tightness23 (11.9%)34 (17.7%)
Highest temperature on admission, mean, (SD) °C37 (17.4)98.4 (17.4)
Lowest O2 saturation on admission, mean, (SD) %98.3 (1.1)98.3 (1.2)
  • ACEI, ACE inhibitors.